Argenx CIDP Data Set To Attract Big Pharma Suitors

Pipeline-In-A-Product Vyvgart Sweeps Through Another Phase III

The very positive Vyvgart ADHERE data in chronic inflammatory demyelinating polyneuropathy, the recent approval for the subcutaneous version for generalized myasthenia gravis and the drug's already strong sales mean that Argenx will again be at the top of the M&A targets tree.

Lions
On the prowl: Pharma's big cats are looking for assets • Source: Shutterstock

argenx N.V.'s position as one of the crown jewels of the European biotech sector, and a rumored takeover target for big pharma, has been enhanced by positive late-stage data on its pipeline-in-a-product Vyvgart in chronic inflammatory demyelinating polyneuropathy (CIDP).

The Belgian-Dutch group has unveiled topline results from the Phase III ADHERE study evaluating the subcutaneous version of the drug, Vyvgart Hytrulo (efgartigimod alfa/hyaluronidase), in adults with CIDP

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

Q1 S&E In Brief: Tracking New Launches And Catalysts In Biopharma

 

Neurocrine, Madrigal and Vanda updated investors on new drug launches, while Cytokinetics talked to investors about an FDA extension for aficamten.

Pharma Left Hanging After US/UK Trade Pact

 
• By 

An ‘historic economic prosperity deal’ does not include the sector.

Chinese Vaccine Makers Turn To Emerging Markets

 

Chinese producers of novel vaccines are increasingly pivoting to developing markets overseas in the face of a collapse in their domestic sales.

Verastem Wins Approval For Novel Drug Combo In Rare Ovarian Cancer

 

The novel RAF/MEK inhibitor and FAK inhibitor are the first treatment approved specifically for KRAS-mutated recurrent low-grade serious ovarian cancer (LGSOC).

More from Business

Building Up US Biopharma Manufacturing Will Require Investments In Talent

 

Workforce development will be essential to meeting president Trump’s goal to return biopharma manufacturing to the US.

Finance Watch: Deerfield Closes $600m-Plus VC Fund; Gates Speeds Up Health Investments

 
• By 

Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.

Pharma Left Hanging After US/UK Trade Pact

 
• By 

An ‘historic economic prosperity deal’ does not include the sector.